Rakuten Group, Inc. is a prominent player in the Consumer Cyclical sector, specifically operating within the highly competitive Internet Retail industry. Currently, the company boasts a massive market capitalization of 1.56 Trillion. Despite its immense scale, Rakuten has been facing noticeable short-term market pressure, as evidenced by a recent 7-day price drop of -7.13%, bringing the current trading price down to JPY720.60.

From a technical standpoint, our proprietary scoring system assigns Rakuten a total score of -2, translating directly to a Sell rating. The stock's primary trend is firmly bearish, with the current price sitting well below its 200-day Simple Moving Average (SMA) of JPY892.34, which removes 2 points from the score. Trend strength indicators confirm this persistent downward momentum; an ADX of 31.21 combined with a dominant DMI- over DMI+ clearly signals a strong bear trend (-1 point). Additionally, volume metrics lean negative, as the On-Balance Volume (OBV) trails its 5-day SMA, indicating distribution (-1 point). However, there are minor counter-signals for aggressive counter-trend traders: an RSI of 28.98 suggests the asset is deeply oversold (+1 point), and a marginally positive MACD histogram hints at a slight bullish crossover (+1 point). Despite these minor momentum shifts, the overarching technical posture remains severely compromised.

In conclusion, this technical weakness aligns closely with Rakuten's underlying fundamental challenges. The absence of a measurable P/E ratio and a 0% dividend yield offer virtually no downside protection for value-oriented investors. Recent earnings data further corroborates this bearish outlook; the latest reported EPS was drastically negative at -13.12, reflecting a massive downside earnings surprise of -63175.0%. With the next major earnings update slated for 14/05/2026, the intersection of poor technical momentum and highly troubled fundamentals strongly justifies our current Sell recommendation.

Merck KGaA, a prominent player in the Healthcare sector, specifically operating within the Drug Manufacturers - Specialty & Generic industry, currently boasts a market capitalization of approximately 45.67 Billion. Recently, the stock has experienced notable downward pressure, reflecting a short-term dip with a 24-hour decline of 1.73% and a 7-day drop of 3.93%, currently trading at EUR 105.05.

Based on our proprietary technical scoring system, Merck KGaA currently holds a Sell rating, driven by a total score of -3. The primary contributor to this bearish outlook is the prevailing trend: the current price sits firmly below the 200-day Simple Moving Average (SMA) of 115.18, resulting in a -2 penalty. This bearish momentum is validated by a strong ADX reading of 35.92 combined with the DMI- (33.90) significantly overpowering the DMI+ (15.93), subtracting another point. Additionally, the MACD histogram is negative (-0.02), signaling a bearish crossover. On the relatively positive side, the RSI currently sits at a neutral 35.07, just above the oversold threshold, and the On-Balance Volume (OBV) recently pushed above its 5-period SMA, hinting at some mild underlying accumulation that added a single point (+1) to the score, preventing a steeper downgrade.

Fundamentally, the stock presents an intriguing divergence from its technical weakness. Merck KGaA trades at a reasonable P/E ratio of 17.51 and features a reported dividend yield of 209.0. From an earnings perspective, the company recently delivered an EPS of 1.5, representing a massive positive surprise of 514.0%. Despite these robust fundamental figures and a spectacular recent earnings beat, the technical chart remains heavily skewed to the downside. Investors should approach with caution and look toward the next scheduled earnings report on 13/05/2026 for potential catalysts that might reverse the current bearish trend.

NatWest Group plc is a prominent institution operating within the Financial Services sector, specifically classified under the Banks - Regional industry. Currently commanding a substantial market capitalization of $58.47 Billion, the stock is trading at $14.60. While the shares have experienced a modest 1.39% uptick over the past 24 hours, they remain slightly down by 1.06% over the trailing seven days, highlighting a period of consolidation for the banking giant.

According to our proprietary technical scoring system, NatWest Group plc receives a Hold rating, driven by a total score of -1. The overarching trend is leaning bearish, as the current price of $14.60 trades just below the 200-day Simple Moving Average of $14.74, resulting in a -2 point penalty. This bearish structure is supported by a strong directional trend, with an ADX of 29.15 and the DMI- (37.42) dominating the DMI+ (20.34), deducting an additional point. Momentum is currently neutral, with the RSI at 42.49 keeping it safely out of oversold territory (0 points). However, short-term indicators offer some pushback against the bears: a positive MACD histogram adds 1 point for bullish crossover, and the On-Balance Volume (OBV) sits comfortably above its 5-day SMA, indicating recent accumulation and contributing another +1 point. This tug-of-war between long-term bearish trends and short-term bullish volume cements the neutral stance.

Looking at the fundamental and earnings context, the Hold rating seems highly appropriate. On the value front, NatWest boasts an attractive P/E ratio of 8.06 and an exceptionally high reported dividend yield figure. Nevertheless, recent financial performance has been deeply concerning. The latest reported EPS came in at just 0.07, paired with a massive, negative earnings surprise of -3124.0%. With the next major quarterly earnings report scheduled far out on 01/05/2026, investors face a prolonged wait for fundamental clarity. Given the mixed technical signals and the severe earnings miss, waiting on the sidelines is the most prudent strategy.

Fulgent Genetics, Inc. is a prominent player in the Healthcare sector, specifically operating within the Diagnostics & Research industry. Currently commanding a market capitalization of $520.61 Million, the stock has recently exhibited notable short-term volatility. Trading at $16.67, the asset has experienced a 2.02% gain over the last 24 hours and an impressive 11.51% surge over the past seven days. Despite this recent upward momentum, the broader technical and fundamental picture demands a careful, nuanced analysis.

Based on our proprietary technical scoring system, Fulgent Genetics earns a Total Score of -1, which translates to a Hold rating. The long-term trend remains firmly bearish, penalizing the stock with a -2 score, as the current price ($16.67) trades significantly below its 200-day Simple Moving Average of $22.72. This downward pressure is structurally confirmed by our trend strength indicator (-1 score): an elevated ADX of 36.73 coupled with the DMI- (29.12) outpacing the DMI+ (22.75). The RSI currently sits in a neutral zone at 43.13. However, short-term momentum indicators offer a glimmer of hope. The MACD histogram has turned positive (+1 score), signaling a bullish crossover, while the On-Balance Volume (OBV) sits comfortably above its 5-day moving average (+1 score), suggesting recent accumulation by active buyers.

In conclusion, this mixed technical outlook closely aligns with a highly challenging fundamental and earnings context. The company currently lacks a calculable P/E ratio—reflecting underlying profitability struggles—and offers no dividend yield to cushion volatility. Its latest earnings report revealed an EPS of -$0.03, accompanied by a staggering negative surprise of -24286.0%. With the next quarterly update slated for 01/05/2026, investors face an extended horizon of uncertainty. While historical fundamentals and long-term technicals scream caution, the recent short-term uptick in buying volume and MACD momentum prevents a full bearish downgrade, solidifying our prudent Hold stance.